Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer

Managed Care Cast

Cholangiocarcinoma—or biliary duct cancer—affects about 8000 US patients a year. On this episode of Managed Care Cast, we bring you an excerpt of an interview with Jesper B. Andersen, PhD, associate professor and group leader at the University of Copenhagen and the Biotech Research and Innovation center at the Department of Health. There have been 3 FDA drug approvals for drugs that treat cholangiocarcinoma, but only for patients that have certain mutations or rearrangements, signifying an unmet need, noted Andersen. And due to the limited number of patients, clinical trials are challenging. Dr Anderson spoke recently with Brielle Benyon, senior editor of CURE®, a publication by MJH Life Sciences. You can watch this interview and many others with by Visiting Medicalworldnews.com, where you can get expert insights you won’t find anywhere else.